152 related articles for article (PubMed ID: 20859246)
1. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment.
Lin KM; Chiu YF; Tsai IJ; Chen CH; Shen WW; Liu SC; Lu SC; Liu CY; Hsiao MC; Tang HS; Liu SI; Chang LH; Wu CS; Tsou HH; Tsai MH; Chen CY; Wang SM; Kuo HW; Hsu YT; Liu YL
Pharmacogenet Genomics; 2011 Apr; 21(4):163-70. PubMed ID: 20859246
[TBL] [Abstract][Full Text] [Related]
2. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
[TBL] [Abstract][Full Text] [Related]
3. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression.
Mihaljevic Peles A; Bozina N; Sagud M; Rojnic Kuzman M; Lovric M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1439-44. PubMed ID: 18550244
[TBL] [Abstract][Full Text] [Related]
4. ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population.
Ozbey G; Yucel B; Taycan SE; Kan D; Bodur NE; Arslan T; Percin F; Yuksel N; Guzey C; Uluoglu C
Pharmacol Rep; 2014 Apr; 66(2):235-8. PubMed ID: 24911075
[TBL] [Abstract][Full Text] [Related]
5. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.
Muhonen LH; Lahti J; Alho H; Lönnqvist J; Haukka J; Saarikoski ST
Psychiatry Res; 2011 Mar; 186(1):53-7. PubMed ID: 20800901
[TBL] [Abstract][Full Text] [Related]
6. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.
Papiol S; Arias B; Gastó C; Gutiérrez B; Catalán R; Fañanás L
J Affect Disord; 2007 Dec; 104(1-3):83-90. PubMed ID: 17467808
[TBL] [Abstract][Full Text] [Related]
7. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder.
Choi MJ; Kang RH; Lim SW; Oh KS; Lee MS
Brain Res; 2006 Nov; 1118(1):176-82. PubMed ID: 16979146
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
9. Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study.
Menu P; Gressier F; Verstuyft C; Hardy P; Becquemont L; Corruble E
Neuropsychobiology; 2010 Aug; 62(3):193-7. PubMed ID: 20664232
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
Fantino B; Moore N; Verdoux H; Auray JP
Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
Demyttenaere K; Hemels ME; Hudry J; Annemans L
Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
13. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders.
Kronenberg S; Apter A; Brent D; Schirman S; Melhem N; Pick N; Gothelf D; Carmel M; Frisch A; Weizman A
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):741-50. PubMed ID: 18315446
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
Singh AB; Bousman CA; Ng CH; Byron K; Berk M
Transl Psychiatry; 2012 Nov; 2(11):e198. PubMed ID: 23188198
[TBL] [Abstract][Full Text] [Related]
15. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Bech P; Andersen HF; Wade A
Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
[TBL] [Abstract][Full Text] [Related]
16. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.
Nikisch G; Eap CB; Baumann P
Pharmacol Res; 2008; 58(5-6):344-7. PubMed ID: 18940259
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphism in the drug transporter gene ABCB1 in treatment-resistant depression: clinical practice.
Rosenhagen MC; Uhr M
J Clin Psychopharmacol; 2010 Apr; 30(2):209-11. PubMed ID: 20520302
[No Abstract] [Full Text] [Related]
20. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
